Piper Sandler keeps BioMarin at Overweight, lifts price target
Piper Sandler maintains BioMarin Pharmaceutical at Overweight and raises its price target to $90.00 per share from $88.00.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.